Mind Medicine (MindMed) Inc
MNMD12.100USD
-0.190-1.55%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
917.22MMarket Cap
LossP/E TTM
More Details of Mind Medicine (MindMed) Inc Company
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed) Inc Info
Ticker SymbolMNMD
Company nameMind Medicine (MindMed) Inc
IPO dateMay 04, 2015
CEOMr. Robert (Rob) Barrow
Number of employees74
Security typeOrdinary Share
Fiscal year-endMay 04
AddressOne World Trade Center
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10007
Phone12122206633
Websitehttps://ir.mindmed.co/
Ticker SymbolMNMD
IPO dateMay 04, 2015
CEOMr. Robert (Rob) Barrow
Company Executives of Mind Medicine (MindMed) Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Daniel R. Karlin, M.D.
Dr. Daniel R. Karlin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Matthew T. Wiley
Mr. Matthew T. Wiley
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Chris Brinzey
Mr. Chris Brinzey
IR Contact Officer
IR Contact Officer
--
--
Mr. Andreas R. Krebs
Mr. Andreas R. Krebs
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert (Rob) Barrow
Mr. Robert (Rob) Barrow
Chief Executive Officer, Director
Chief Executive Officer, Director
224.25K
-10.32%
Mr. Mark R. Sullivan
Mr. Mark R. Sullivan
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.35K
-26.46%
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
17.64K
+44.14%
Dr. Roger Crystal, M.D.
Dr. Roger Crystal, M.D.
Independent Director
Independent Director
17.64K
+44.14%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
10.62K
-46.52%
Ms. Carol A. Vallone
Ms. Carol A. Vallone
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Other
79.04%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
5.38%
Commodore Capital LP
5.16%
Blackstone Alternative Asset Management, L.P.
3.70%
Marshall Wace LLP
3.53%
Driehaus Capital Management, LLC
3.19%
Other
79.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
22.81%
Hedge Fund
16.77%
Investment Advisor
13.84%
Research Firm
1.64%
Individual Investor
1.03%
Bank and Trust
0.36%
Pension Fund
0.19%
Venture Capital
0.17%
Insurance Company
0.04%
Other
43.15%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
383
42.48M
55.83%
-5.92M
2025Q2
380
42.59M
55.97%
-6.05M
2025Q1
383
42.99M
56.91%
-5.37M
2024Q4
358
42.80M
58.58%
-14.39M
2024Q3
346
50.91M
62.84%
+1.65M
2024Q2
371
44.11M
63.15%
+4.97M
2024Q1
368
37.27M
54.54%
+28.87M
2023Q4
362
7.25M
18.10%
-366.43K
2023Q3
378
6.32M
16.16%
-494.13K
2023Q2
386
6.41M
16.75%
-688.87K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.22M
6.86%
+17.02K
+0.33%
Jun 30, 2025
Commodore Capital LP
5.00M
6.57%
+475.00K
+10.50%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.59M
4.71%
--
--
Jun 30, 2025
Marshall Wace LLP
3.42M
4.5%
+828.07K
+31.93%
Jun 30, 2025
Driehaus Capital Management, LLC
3.09M
4.06%
-258.75K
-7.72%
Jun 30, 2025
Deep Track Capital LP
2.50M
3.29%
--
--
Jun 30, 2025
Octagon Capital Advisors LP
2.13M
2.8%
-888.00K
-29.42%
Jun 30, 2025
State Street Investment Management (US)
1.81M
2.37%
-36.32K
-1.97%
Jun 30, 2025
The Vanguard Group, Inc.
1.80M
2.37%
+47.45K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.73M
2.28%
+66.66K
+4.00%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
AdvisorShares Psychedelics ETF
10.44%
SPDR S&P Pharmaceuticals ETF
1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.25%
Virtus LifeSci Biotech Clinical Trials ETF
1.17%
iShares U.S. Pharmaceuticals ETF
0.33%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
Vanguard US Momentum Factor ETF
0.07%
Nuveen ESG Small-Cap ETF
0.06%
View more
AdvisorShares Psychedelics ETF
Proportion10.44%
SPDR S&P Pharmaceuticals ETF
Proportion1.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.25%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.17%
iShares U.S. Pharmaceuticals ETF
Proportion0.33%
iShares Micro-Cap ETF
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.09%
Vanguard US Momentum Factor ETF
Proportion0.07%
Nuveen ESG Small-Cap ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Date
Type
Ratio
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
Aug 23, 2022
Merger
15→1
